Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia
Vijay Sagar Madamsetty(Jacksonville College), Asher Chanan‐Khan(WinnMed), Sharoon Akhtar(Mayo Clinic in Florida), Debabrata Mukhopadhyay(Jacksonville College), Hari Krishnareddy Rachamalla(Indian Institute of Chemical Technology), Alak Manna(Institute of Post Graduate Medical Education and Research), Rintu Banerjee(Indian Institute of Chemical Technology), Aneel Paulus(WinnMed)
Cited by 6
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
|Blood|2011|450
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
|Blood|2017|271
In vivo gene delivery mediated by non-viral vectors for cancer therapy
|Journal of Controlled Release|2020|240
Recent Trends of the Bio-Inspired Nanoparticles in Cancer Theranostics
|Frontiers in Pharmacology|2019|210